Cargando…
Pharmacokinetics, Excretion, and Mass Balance of [(14)C]‐Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men
Inhaled batefenterol is an investigational bifunctional molecule for the treatment of chronic obstructive pulmonary disease. The excretion balance and pharmacokinetics of batefenterol using [(14)C]‐radiolabeled drug administered orally and as intravenous (IV) infusion were assessed. In this 2‐period...
Autores principales: | Ambery, Claire, Young, Graeme, Fuller, Teresa, Lazaar, Aili L., Pereira, Adrian, Hughes, Adam, Ramsay, David, van den Berg, Frans, Daley‐Yates, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282586/ https://www.ncbi.nlm.nih.gov/pubmed/30230263 http://dx.doi.org/10.1002/cpdd.616 |
Ejemplares similares
-
Open‐Label, Crossover Study to Determine the Pharmacokinetics of Fluticasone Furoate and Batefenterol When Administered Alone, in Combination, or Concurrently
por: Ambery, Claire, et al.
Publicado: (2018) -
Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD
por: Crim, Courtney, et al.
Publicado: (2019) -
Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination
por: Mahar, Kelly M., et al.
Publicado: (2021) -
A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD
por: Crim, Courtney, et al.
Publicado: (2020) -
Population Pharmacokinetics and Pharmacodynamics of GSK961081 (Batefenterol), a Muscarinic Antagonist and β(2)-Agonist, in Moderate-to-Severe COPD Patients: Substudy of a Randomized Trial
por: Ambery, Claire L., et al.
Publicado: (2015)